FY2024 Earnings Estimate for IQVIA Issued By Leerink Partnrs

IQVIA Holdings Inc. (NYSE:IQV) – Stock analysts at Leerink Partnrs boosted their FY2024 earnings estimates for shares of IQVIA in a report released on Tuesday, December 10th. Leerink Partnrs analyst M. Cherny now forecasts that the medical research company will post earnings of $10.13 per share for the year, up from their previous forecast of $10.07. The consensus estimate for IQVIA’s current full-year earnings is $10.17 per share. Leerink Partnrs also issued estimates for IQVIA’s FY2026 earnings at $12.26 EPS and FY2027 earnings at $13.70 EPS.

A number of other equities analysts have also recently commented on IQV. Leerink Partners reaffirmed an “outperform” rating and set a $248.00 price objective (down from $260.00) on shares of IQVIA in a research report on Tuesday, November 19th. Barclays reduced their price target on IQVIA from $260.00 to $255.00 and set an “overweight” rating for the company in a research note on Friday, November 1st. JPMorgan Chase & Co. lowered their price objective on IQVIA from $279.00 to $240.00 and set an “overweight” rating on the stock in a research report on Tuesday, November 5th. Morgan Stanley decreased their price target on shares of IQVIA from $280.00 to $265.00 and set an “overweight” rating on the stock in a research note on Monday, November 4th. Finally, TD Cowen decreased their target price on shares of IQVIA from $270.00 to $255.00 and set a “buy” rating on the stock in a research report on Friday, November 1st. Four research analysts have rated the stock with a hold rating, sixteen have issued a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $256.19.

IQVIA Price Performance

Shares of NYSE IQV opened at $199.06 on Friday. IQVIA has a twelve month low of $187.62 and a twelve month high of $261.73. The company has a market cap of $36.13 billion, a PE ratio of 26.12, a price-to-earnings-growth ratio of 2.07 and a beta of 1.49. The business’s 50 day moving average price is $212.24 and its two-hundred day moving average price is $224.21. The company has a quick ratio of 0.81, a current ratio of 0.81 and a debt-to-equity ratio of 1.76.

Institutional Trading of IQVIA

Large investors have recently added to or reduced their stakes in the stock. FMR LLC grew its holdings in IQVIA by 38.7% during the third quarter. FMR LLC now owns 2,887,342 shares of the medical research company’s stock valued at $684,213,000 after purchasing an additional 804,963 shares during the period. B. Metzler seel. Sohn & Co. Holding AG bought a new position in shares of IQVIA in the third quarter worth $147,683,000. 1832 Asset Management L.P. boosted its stake in IQVIA by 472.3% during the second quarter. 1832 Asset Management L.P. now owns 456,335 shares of the medical research company’s stock valued at $96,487,000 after buying an additional 376,595 shares during the period. Renaissance Technologies LLC purchased a new position in IQVIA during the second quarter worth about $70,610,000. Finally, Impax Asset Management Group plc increased its stake in IQVIA by 19.3% in the 2nd quarter. Impax Asset Management Group plc now owns 1,635,201 shares of the medical research company’s stock worth $344,998,000 after acquiring an additional 264,555 shares during the last quarter. Hedge funds and other institutional investors own 89.62% of the company’s stock.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.